Covered recipient · General Payments record
JENNIFER O HILL
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2021–2024
$465.20
- Reported across 18 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $327.17 | 10 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $204.31 | 5 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $34.75 | 1 |
| Gilead Sciences, Inc. | $24.80 | 1 |
| Lilly USA, LLC | $21.42 | 1 |
| Vanda Pharmaceuticals Inc. | $21.24 | 1 |
| CSL Behring | $20.65 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (10)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| CSL Behring | $20.65 | 03/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134626967 | CMS |
| Gilead Sciences, Inc. | $24.80 | 10/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133633696 | CMS |
| Lilly USA, LLC | $21.42 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135042620 | CMS |
| Novartis Pharmaceuticals Corporation | $34.75 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086920685 | CMS |
| Novo Nordisk Inc | $50.00 | 03/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097409056 | CMS |
| Novo Nordisk Inc | $19.85 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097714076 | CMS |
| Novo Nordisk Inc | $87.69 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097302532 | CMS |
| Novo Nordisk Inc | $20.59 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097421553 | CMS |
| Novo Nordisk Inc | $26.18 | 10/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096929370 | CMS |
| Vanda Pharmaceuticals Inc. | $21.24 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133906339 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.